Sunshine Biopharma Valuation
| SBFM Stock | USD 2.28 0.05 2.24% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Sunshine Biopharma has a current Real Value of $76.66 per share. The regular price of the company is $2.28. Our model measures the value of Sunshine Biopharma from inspecting the company fundamentals such as Operating Margin of (0.13) %, shares outstanding of 2.71 M, and Return On Equity of -0.18 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Sunshine Biopharma's valuation include:
Price Book 0.2316 | Enterprise Value | Enterprise Value Ebitda (7.73) | Price Sales 0.1832 | Enterprise Value Revenue 39.4772 |
Undervalued
Today
Please note that Sunshine Biopharma's price fluctuation is very steady at this time. Calculation of the real value of Sunshine Biopharma is based on 3 months time horizon. Increasing Sunshine Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Sunshine stock is determined by what a typical buyer is willing to pay for full or partial control of Sunshine Biopharma. Since Sunshine Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sunshine Stock. However, Sunshine Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.28 | Real 76.66 | Target 300.0 | Hype 2.31 | Naive 2.33 |
The intrinsic value of Sunshine Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sunshine Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sunshine Biopharma helps investors to forecast how Sunshine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sunshine Biopharma more accurately as focusing exclusively on Sunshine Biopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Sunshine Biopharma's intrinsic value based on its ongoing forecasts of Sunshine Biopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Sunshine Biopharma's closest peers.
Sunshine Biopharma Cash |
|
Sunshine Valuation Trend
Knowing Sunshine Biopharma's actual value is paramount for traders when making sound investment determinations. Using both Sunshine Biopharma's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Sunshine Valuation Data Drivers
Sunshine Biopharma Total Value Analysis
Sunshine Biopharma is at this time forecasted to have valuation of (5.84 M) with market capitalization of 6.04 M, debt of 657.71 K, and cash on hands of 41.74 M. The negative valuation of Sunshine Biopharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Sunshine Biopharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(5.84 M) | 6.04 M | 657.71 K | 41.74 M |
Sunshine Biopharma Investor Information
The company has price-to-book ratio of 0.23. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sunshine Biopharma recorded a loss per share of 127.9. The entity last dividend was issued on the 6th of April 2020. The firm had 1:20 split on the 8th of August 2024. Based on the key measurements obtained from Sunshine Biopharma's financial statements, Sunshine Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Sunshine Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sunshine Biopharma has an asset utilization ratio of 88.1 percent. This suggests that the Company is making $0.88 for each dollar of assets. An increasing asset utilization means that Sunshine Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Sunshine Biopharma Ownership Allocation
Sunshine Biopharma has 7.22 % of its outstanding shares held by insiders and 1.12 % owned by institutional holders.Sunshine Biopharma Profitability Analysis
The company reported the previous year's revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 10.14 M.About Sunshine Biopharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Sunshine Biopharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Sunshine Biopharma based exclusively on its fundamental and basic technical indicators. By analyzing Sunshine Biopharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Sunshine Biopharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Sunshine Biopharma. We calculate exposure to Sunshine Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sunshine Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 9.6 M | 10.1 M | |
| Pretax Profit Margin | (0.15) | (0.16) | |
| Operating Profit Margin | (0.18) | (0.19) | |
| Net Loss | (0.17) | (0.18) | |
| Gross Profit Margin | 0.31 | 0.33 |
Sunshine Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Sunshine Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 12.2 K |
Sunshine Biopharma Current Valuation Indicators
Sunshine Biopharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Sunshine Biopharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Sunshine Biopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Sunshine Biopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Sunshine Biopharma's worth.When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share | Quarterly Revenue Growth 0.416 | Return On Assets | Return On Equity |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.